Platelet Function After Cardiac Surgery. - Trial NCT06405516
Access comprehensive clinical trial information for NCT06405516 through Pure Global AI's free database. This phase not specified trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Not yet recruiting. The study focuses on Platelet Dysfunction. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Insel Gruppe AG, University Hospital Bern
Timeline & Enrollment
N/A
May 01, 2024
Jan 01, 2025
Primary Outcome
Platelet number
Summary
Intraoperative cell salvage is commonly used in cardiac surgery to reduce the administration
 of allogeneic red blood cells and thus improve the outcome for the patient. When processing
 the salvaged blood, however, a large part of the patient's plasma is washed out. This is a
 disadvantage with regard to an optimal coagulation situation after cardiac surgery.
 
 There are currently various cell saver systems on the market. According to the manufacturers,
 the plasma is returned to the patient in different quantities as part of the processing
 procedure. Thus, it can be assumed that in addition to red blood cells, platelets (part of
 plasma) are retransfused and contribute to an optimized coagulation. Unfortunately, there is
 a lack of studies in this regard in the cardiac surgery population.
 
 The investigators aim to study the performance of two different cell saver devices regarding
 preservation of platelet number and function.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06405516
Device Trial